Literature DB >> 8818892

Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.

L Zerva1, D J Biedenbach, R N Jones.   

Abstract

A collection of 300 Haemophilus influenzae clinical strains was used to assess in vitro susceptibility to carbapenems (meropenem, imipenem) by MIC and disk diffusion methods and to compare disk diffusion test results with two potencies of ampicillin disks (2 and 10 micrograms). The isolates included ampicillin-susceptible or- intermediate (167 strains), beta-lactamase-positive (117 strains), and beta-lactamase-negative ampicillin-resistant (BLNAR; 16 strains) organisms. Disk diffusion testing was performed with 10-micrograms meropenem disks from two manufacturers. Meropenem was highly active against H. influenzae strains (MIC50, 0.06 microgram/ml; MIC90, 0.25 microgram/ml; MIC50 and MIC90, MICs at which 50 and 90%, respectively, of strains are inhibited) and was 8- to 16-fold more potent than imipenem (MIC50, 1 microgram/ml; MIC90, 2 micrograms/ml). Five non-imipenem-susceptible strains were identified (MIC, 8 micrograms/ml), but the disk diffusion test indicated susceptibility (zone diameters, 18 to 21 mm). MIC values of meropenem, doxycycline, ceftazidime, and ceftriaxone for BLNAR strains were two- to fourfold greater than those for other strains. The performance of both meropenem disks was comparable and considered acceptable. A single susceptible interpretive zone diameter of > or = 17 mm (MIC, < = or 4 micrograms/ml) was proposed for meropenem. Testing with the 2-micrograms ampicillin disk was preferred because of an excellent correlation between MIC values and zone diameters (r = 0.94) and superior interpretive accuracy with the susceptible criteria at > or = 17 mm (MIC, < or = 1 microgram/ml) and the resistant criteria at < or = 13 mm (MIC, > or = 4 micrograms/ml). Among the BLNAR strains tested, 81.3% were miscategorized as susceptible or intermediate when the 10-micrograms ampicillin disk was used, while the 2-micrograms disk produced only minor interpretive errors (12.5%). Use of these criteria for testing H. influenzae against meropenem and ampicillin should maximize reference test and standardized disk diffusion test performance with the Haemophilus Test Medium. The imipenem disk diffusion test appears compromised and should be used with caution for detecting strains for which imipenem MICs are elevated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818892      PMCID: PMC229164          DOI: 10.1128/jcm.34.8.1970-1974.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Haemophilus influenzae: then and now.

Authors:  J Z Jordens; M P Slack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Detection of ampicillin resistant Haemophilus influenzae in United Kingdom laboratories.

Authors:  M Powell; J D Williams
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

Review 4.  Review of the in vitro spectrum of activity of imipenem.

Authors:  R N Jones
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

5.  A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates.

Authors:  S F Rittenhouse; L A Miller; R L Kaplan; G H Mosely; J A Poupard
Journal:  Diagn Microbiol Infect Dis       Date:  1995-04       Impact factor: 2.803

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

7.  Ampicillin disk diffusion susceptibility testing of Haemophilus influenzae.

Authors:  G V Doern; G S Daum; T A Tubert
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

8.  The pharmacokinetics of meropenem in surgical patients with moderate or severe infections.

Authors:  A M Lovering; C J Vickery; D S Watkin; D Leaper; C M McMullin; L O White; D S Reeves; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

9.  Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.

Authors:  Y Sumita; M Fukasawa
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

10.  Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.

Authors:  J L Blumer; M D Reed; G L Kearns; R F Jacobs; W M Gooch; R Yogev; K Willims; B J Ewing
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  3 in total

1.  Haemophilus influenzae with Non-Beta-Lactamase-Mediated Beta-Lactam Resistance: Easy To Find but Hard To Categorize.

Authors:  Dagfinn Skaare; Astrid Lia; Anja Hannisdal; Yngvar Tveten; Erika Matuschek; Gunnar Kahlmeter; Bjørn-Erik Kristiansen
Journal:  J Clin Microbiol       Date:  2015-09-09       Impact factor: 5.948

2.  Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.

Authors:  Silvia García-Cobos; José Campos; Federico Román; Cristina Carrera; María Pérez-Vázquez; Belén Aracil; Jesús Oteo
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

3.  Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae.

Authors:  Henri Dabernat; Catherine Delmas; Martine Seguy; Roseline Pelissier; Genevieve Faucon; Safia Bennamani; Christophe Pasquier
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.